Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay

Clinical Biochemistry

Volumn 49, Issue 15, 2016, Pages 1202-1204

  Rosenberg, Aaron Seth ^a   Bainbridge, Scott ^b   Pahwa, Roma ^b   Jialal, Ishwarlal ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti CD38; Daratumumab; Free light chains; Monoclonal antibodies; Myeloma

Indexed keywords

DARATUMUMAB; IMMUNOGLOBULIN A KAPPA; IMMUNOGLOBULIN A LAMBDA; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M KAPPA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY;

ARTICLE; ASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FREE LIGHT CHAIN ASSAY; HUMAN; LIMIT OF DETECTION; PRIORITY JOURNAL; ELECTROPHORESIS; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ELECTROPHORESIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS;

EID: 84992034885     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.07.016     Document Type: Article

References (15)

1. [1] Dimopoulos, M., Kyle, R., Fermand, J.P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:18 (2011), 4701–4705.
2. [2] Dispenzieri, A., Kyle, R., Merlini, G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:2 (2009), 215–224.
3. [3] Dispenzieri, A., Kyle, R.A., Katzmann, J.A., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:2 (2008), 785–789.
4. [4] Alhaj Moustafa, M., Rajkumar, S.V., Dispenzieri, A., et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia 29:10 (2015), 2033–2038.
5. [5] Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:1 (2009), 3–9.
6. [6] Rajkumar, S.V., Harousseau, J.L., Durie, B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:18 (2011), 4691–4695.
7. [7] Lakshminarayanan, R., Li, Y., Janatpour, K., Beckett, L., Jialal, I., Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. Am. J. Clin. Pathol. 127:5 (2007), 746–751.
8. [8] Raje, N., Longo, D.L., Monoclonal antibodies in multiple myeloma come of age. N. Engl. J. Med. 373:13 (2015), 1264–1266.
9. [9] Dimopoulos, M.A., Richardson, P.G., Moreau, P., Anderson, K.C., Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat. Rev. Clin. Oncol. 12:1 (2015), 42–54.
10. [10] Lokhorst, H.M., Plesner, T., Laubach, J.P., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373:13 (2015), 1207–1219.
11. [11] van de Donk, N.W., Moreau, P., Plesner, T., et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127:6 (2016), 681–695.
12. [12] Lonial, S., Weiss, B.M., Usmani, S.Z., et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:10027 (2016), 1551–1560.
13. [13] Rajkumar, S.V., Daratumumab in multiple myeloma. Lancet, 2016.
14. [14] van de Donk, N.W., Otten, H.G., El Haddad, O., et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin. Chem. Lab. Med., 2016.
15. [15] McCudden, C., Axel, A.E., Slaets, D., et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin. Chem. Lab. Med., 2016.